PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsOrphenadrine
Orphenadrine
Disipal, Orphenadrine, Orphengesic (orphenadrine) is a small molecule pharmaceutical. Orphenadrine was first approved as Norflex on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, myositis, pain, and spasm amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Orphenadrine (discontinued: Disipal, Norflex, Orphenadrine)
Combinations
Orphengesic (discontinued: Invagesic, Norgesic, Orphenadrine citrate, aspirin, caffeine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Orphenadrine hydrochloride
Tradename
Company
Number
Date
Products
DISIPAL3MN-010653 DISCN1982-01-01
1 products
Hide discontinued
Orphenadrine citrate
Tradename
Company
Number
Date
Products
NORFLEXBausch Health CompaniesN-012157 DISCN1982-01-01
1 products, RLD
NORFLEXPAI PharmaN-013055 DISCN1982-01-01
1 products, RLD
Hide discontinued
Aspirin
+
Caffeine
+
Orphenadrine citrate
Tradename
Company
Number
Date
Products
NORGESICBausch Health CompaniesN-013416 DISCN1982-10-27
1 products, RLD
NORGESIC FORTEBausch Health CompaniesN-013416 DISCN1982-10-27
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
norflexANDA2020-12-04
norgesicANDA2024-01-08
norgesic forteANDA2024-01-27
orphenadrine citrateANDA2025-09-10
orphenadrine citrate aspirin caffeineANDA2024-07-25
orphenadrine citrate exended-release2008-04-09
orphenadrine citrate, aspirin and caffeineANDA2025-01-13
orphengesic forteANDA2024-12-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myositisEFO_0000783D009220G72.49
painEFO_0003843D010146R52
muscle cramp—D009120—
spasm—D013035M62.83
tetanusEFO_0005593D013742A35
muscle rigidity—D009127—
rheumatoid arthritisEFO_0000685D001172M06.9
fever—D005334R50.9
inflammationMP_0001845D007249—
osteoarthritisEFO_0002506D010003M15-M19
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BC: Ethers chemically close to antihistamines, centrally acting muscle relaxants
— M03BC01: Orphenadrine (citrate)
— M03BC51: Orphenadrine, combinations
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04A: Anticholinergic agents
— N04AB: Ethers chemically close to antihistamines, anticholinergic
— N04AB02: Orphenadrine (chloride)
HCPCS
Code
Description
J2360
Injection, orphenadrine citrate, up to 60 mg
Clinical
Clinical Trials
17 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Muscle hypotoniaD009123—————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOrphenadrine
INNorphenadrine
Description
Orphenadrine is a tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. It has a role as a NMDA receptor antagonist, a H1-receptor antagonist, an antiparkinson drug, a parasympatholytic, a muscle relaxant, a muscarinic antagonist and an antidyskinesia agent. It is a tertiary amino compound and an ether.
Classification
Small molecule
Drug classsympathomimetics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccccc1C(OCCN(C)C)c1ccccc1
Identifiers
PDB—
CAS-ID83-98-7
RxCUI—
ChEMBL IDCHEMBL900
ChEBI ID7789
PubChem CID4601
DrugBankDB01173
UNII IDAL805O9OG9 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Orphenadrine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,295 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
936 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use